Compare Ginkgo Bioworks Holdings Inc (DNA) vs Ferrari NV (RACE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Ferrari NV — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.08 (market cap $590.53M), while Ferrari NV trades at $375.48 (market cap $65.00B). The key difference: Ferrari NV is far larger — about 110.1× Ginkgo Bioworks Holdings Inc's market cap, and Ferrari NV pays a 1.14% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | RACE | |
|---|---|---|
Market Cap | $590.53M | $65.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $16.14 | $517.65 |
52-Week Low | $5.48 | $314.63 |
Enterprise Value | $627.78M | $66.21B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Ferrari (RACE) trades at $372.98, down 0.97% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong profitability with a net income margin of 22.19% and robust revenue growth from $5.1B in 2022 to $7.1B in 2025. Recent news highlights the company's ongoing share buyback program and strategic moves in the EV space, though the Luce model has faced some market skepticism.
The outlook remains positive with a consensus price target of $467.50, implying significant upside. Key opportunities include pricing power and margin strength, while risks involve execution on EV strategy and high valuation multiples. Earnings consistently beat expectations, supporting the bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
